Drug intelligence / Profile preview

XTL-686

Development stage: Discontinued
Lead developer: XTL Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

XTL-686 is an orally bioavailable small molecule inhibitor of the Hepatitis C Virus (HCV) NS3/4A serine protease. Developed by XTL Biopharmaceuticals through a licensing agreement with Kureha Corporation, the compound was designed to block viral replication by preventing the proteolytic cleavage of the HCV polyprotein into functional non-structural proteins. XTL-686 was primarily investigated for the treatment of chronic hepatitis C infection. Clinical development reached Phase 1/2 stages; however, the program was ultimately discontinued as the company shifted its strategic focus and the competitive landscape for HCV protease inhibitors evolved rapidly.

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)

Beyond the preview

Go deeper on XTL-686.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XTL-686.

Explore the full profile